Comment on: "Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy".

Abstract

ADVERTISEMENT RETURN TO ISSUEPREVCommunicationNEXTComment on: “Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy”Tian Tian*Tian TianDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China*Email: [email protected]. Tel.: +86-0371-66295561.More by Tian Tianhttps://orcid.org/0000-0002-0796-4561Cite this: Mol. Pharmaceutics 2023, 20, 2, 1447–1448Publication Date (Web):December 28, 2022Publication History Received26 October 2022Accepted23 December 2022Revised22 December 2022Published online28 December 2022Published inissue 6 February 2023https://doi.org/10.1021/acs.molpharmaceut.2c00903Copyright © 2022 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views60Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit Read OnlinePDF (776 KB) Get e-AlertsSUBJECTS:Cancer,Chemotherapy,Drug delivery,Inhibitors,Nanoparticles Get e-Alerts